GS-E3D

Pectin lyase-modified red ginseng extract; composed of 62.39 mg/g crude saponin containing the following ginsenosides: 3.33 mg/g Rg1, 6.41 mg/g Re, 2.24 mg/g Rf, 15.45 mg/g Rb1, 9.92 mg/g Rc, 9.48 mg/g Rb2, and 15.58 mg/g Rd.

Networked: 7 relevant articles (3 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Pyo, Mi-Kyung: 5 articles (01/2021 - 12/2014)
2.	Kim, Junghyun: 3 articles (01/2021 - 08/2017)
3.	Jung, Eunsoo: 2 articles (01/2021 - 04/2019)
4.	Kim, Chan-Sik: 2 articles (04/2019 - 08/2017)
5.	Choi, Hae Young: 1 article (08/2020)
6.	Lee, Jee Youn: 1 article (08/2020)
7.	Park, Chan Sol: 1 article (08/2020)
8.	Yune, Tae Young: 1 article (08/2020)
9.	Chung, Sung Hyun: 1 article (03/2020)
10.	Kim, Go Woon: 1 article (03/2020)

Related Diseases

1.	Obesity 12/01/2014 - "These results suggest that GS-E3D, as a dietary supplement, has beneficial effects on obesity and may have useful effects in health-care products. " 06/01/2019 - "Pectin lyase-modified red ginseng extract (GS-E3D) was newly developed as a dietary supplement for obesity, diabetes-related renal dysfunction, etc. In this study, the safety of GS-E3D on acute toxicity and genotoxicity was evaluated. " 03/01/2020 - "The results collectively show that GS-E3D ameliorates obesity-related impaired glucose tolerance by improving insulin sensitivity in the epidydimal adipose tissue."
2.	Vascular System Injuries 04/01/2019 - "These results indicate that GS-E3D could be a beneficial treatment option for preventing diabetes-induced retinal vascular injury."
3.	Glucose Intolerance 03/01/2020 - "The results collectively show that GS-E3D ameliorates obesity-related impaired glucose tolerance by improving insulin sensitivity in the epidydimal adipose tissue."
4.	Insulin Resistance 03/01/2020 - "Notably, GS-E3D treated mice at doses of 250, 500 and 1000 mg/kg showed 41.8%, 45.0% and 55.1% reduction in insulin resistance index, respectively, compared to HFD control mice. " 03/01/2020 - "The results collectively show that GS-E3D ameliorates obesity-related impaired glucose tolerance by improving insulin sensitivity in the epidydimal adipose tissue."
5.	Diabetic Nephropathies (Diabetic Nephropathy) 08/29/2017 - "Oral administration of GS-E3D dose-dependently improved all symptoms of diabetic nephropathy by inhibiting renal accumulation of AGEs and oxidative stress. "

Related Drugs and Biologics

1.	Retinaldehyde (Retinal)
2.	pectin lyase
3.	Streptozocin (Streptozotocin)
4.	8-Hydroxy-2'-Deoxyguanosine

Related Therapies and Procedures

1.	Oral Administration